Denmark-based biotechnology company Novozymes and Denmark-based bioscience company Chr. Hansen on Jan. 29 announced they have completed a planned merger, creating the newly formed company Novonesis. 

Novozymes and Chr. Hansen in December 2022 entered into an agreement to create a global biosolutions partner through a statutory merger of the two companies. All regulatory approvals and registrations are not in place and the proposed merger was successfully completed on Jan. 29 following the final registration with the Danish Business Authority. 

“We have successfully combined Novozymes and Chr. Hansen and today we come together as one leading global biosolutions partner,” said Ester Baiget, president and CEO of Novonesis. “Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and together with my 10,000 colleagues, we will unlock the limitless potential of biosolutions.”

“I am pleased to witness the realization of the Novozymes and Chr. Hansen combination, creating a true global biosolutions leader,” said Cees de Jong, chairman of Novonesis, adds. “We will continue to create powerful biosolutions for our customers and partners based on our more than 100 years of innovation and application expertise. Together, we will serve as a growth partner to our customers; a value creator to our shareholders; and a company that has a significant, positive impact on society and the planet. Novonesis builds on a shared heritage of sustainability leadership and will keep leading the way.”

A full copy of the announcement is available on the Novozymes website.